Pharma Capital

ANGLE PLC boss 'absolutely delighted' with results from pelvic mass study

ANGLE plc (LON:AGL,OTCQX:ANPCY) founder and chief executive Andrew Newland tells Proactive their ground-breaking liquid biopsy has outperformed current tests used to tell whether a pelvic mass is malignant or benign.

 

View full AGL profile

ANGLE plc Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.